Abstract
Abstract
Background
How best to prioritise COVID-19 vaccination within and between countries has been a public health and an ethical challenge for decision-makers globally. We reviewed epidemiological and economic modelling evidence on population priority groups to minimise COVID-19 mortality, transmission, and morbidity outcomes.
Methods
We searched the National Institute of Health iSearch COVID-19 Portfolio (a database of peer-reviewed and pre-print articles), Econlit, the Centre for Economic Policy Research, and the National Bureau of Economic Research for mathematical modelling studies evaluating the impact of prioritising COVID-19 vaccination to population target groups. The first search was conducted on March 3, 2021, and an updated search on the LMIC literature was conducted from March 3, 2021, to September 24, 2021. We narratively synthesised the main study conclusions on prioritisation and the conditions under which the conclusions changed.
Results
The initial search identified 1820 studies and 36 studies met the inclusion criteria. The updated search on LMIC literature identified 7 more studies. 43 studies in total were narratively synthesised. 74% of studies described outcomes in high-income countries (single and multi-country). We found that for countries seeking to minimise deaths, prioritising vaccination of senior adults was the optimal strategy and for countries seeking to minimise cases the young were prioritised. There were several exceptions to the main conclusion, notably that reductions in deaths could be increased if groups at high risk of both transmission and death could be further identified. Findings were also sensitive to the level of vaccine coverage.
Conclusion
The evidence supports WHO SAGE recommendations on COVID-19 vaccine prioritisation. There is, however, an evidence gap on optimal prioritisation for low- and middle-income countries, studies that included an economic evaluation, and studies that explore prioritisation strategies if the aim is to reduce overall health burden including morbidity.
Funder
World Health Organization
Bill and Melinda Gates Foundation
National Institute for Health Research
European Commission
HDR UK
Medical Research Council
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/. Accessed 20 Sept 2021.
2. World Health Organization. WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination. https://www.who.int/publications/i/item/whosage- values-framework-for-the-allocation-and-prioritization-of-covid-19-vaccination. Accessed 8 June 2021.
3. World Health Organization. WHO Strategic Advisory Group of Experts (SAGE) on Immunization Working Group on COVID-19 Vaccines: Prioritized Infectious Disease and Economic Modelling Questions. https://www.who.int/immunization/policy/sage/SAGE_WG_COVID19_Vaccines_Modelli ng_Questions_31July2020.pdf. Accessed 8 June 2021.
4. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. https://doi.org/10.1136/bmj.b2700.
5. Popay J, Roberts H, Sowden A, Pettricrew M, Arai L, Rodgers M et al. Guidance on the Conduct of Narrative Synthesis in Systematic Reviews. https://www.lancaster.ac.uk/media/lancaster-university/contentassets/ documents/fhm/dhr/chir/NSsynthesisguidanceVersion1-April2006.pdf. Accessed 8 June 2021.
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献